Dr. Mason is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3615 Paper Mill Rd SE
Marietta, GA 30067Phone+1 770-956-3722
Summary
- Dr. David Mason is an internist in Marietta, GA, with subspecialties in rheumatology and infectious diseases. He received his medical degree from Duke University School of Medicine, taught at the University of Michigan, was in practice for 8 years, and has been working in the pharmaceutical, device and biotech industries for 37 years. He is experienced in rheumatoid arthritis, arthritis, and clinical trials in multiple indications. He has led the development of more than fifteen drugs and devices. He has more than 20 publications and over 200 citings.
Education & Training
- University of MichiganResidency, Internal Medicine, 1976 - 1977
- Duke University HospitalInternship, Internal Medicine, 1973 - 1974
- Duke University School of MedicineClass of 1973
- Williams CollegeB.A., Chemistry, Magna Cum Laude, 1965 - 1969
Certifications & Licensure
- GA State Medical License 2008 - 2025
- NC State Medical License 1979 - 2025
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Mosby Award, Class President Duke Medical School, 1973
- Phi Beta Kappa Junior Year, Williams College
- Alpha Omega Alpha Honorary Medical Society, Junior Year Duke University Medical School
- Join now to see all
Publications & Presentations
PubMed
- 107 citationsActive specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated w...Hong M. Moulton, Paul H Yoshihara, David H. Mason, Patrick L. Iversen, Pierre L. Triozzi
Clinical Cancer Research. 2002-07-01 - 97 citationsEfficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans.Patrick L. Iversen, Vikram Arora, AJ Acker, David H. Mason, Gayathri R. Devi
Clinical Cancer Research. 2003-07-01
Journal Articles
- Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study A randomized controlled trialSmolen, J., Landewe, R.B., Mease, P., Brzezicki, J., Mason, D., Luijtens, K., van Vollenhoven, R.F., Kavanaugh, A., Schiff, M., Burmester, G.R., Strand, V., Vencovsky,..., Ann Rheum Dis, 11/1/2008
- Certolizumab Pegol Plus Methotrexate Is Significantly More Effective Than Placebo Plus Methotrexate in Active Rheumatoid ArthritisKeystone, E., van der Heijde, D, Mason, Jr, D, Landewe, R, van Vollenhover, r, Combe, B, Emery, P, Strand, V, Mease, P, Desai, C., and Pavelka, K., Arthritis and Rheumatism, 11/1/2008
- Certolizumab Pegol for the Treatment of Crohn’s DiseaseSandborn, W.J., Feagan, B.G., Stoinov, S., Honiball, P.J., Rutgeerts, P, Mason, D, Bloomfield, R, Schreiber, S, NEJM, 7/1/2007
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: